Back to search
FDAFDA · Food and drugs·Recall number D-015-2014

Affirm XL Nutritional Supplement, 1 and 10 count blister packs and single pill packs, Manufactured by Dongseo Biopharm Corp., Yongin City, Kyonggi do, Korea, distributed by: Affirm XL, LLC, Ladera Ranch, CA

Published November 27, 2013 · Recall initiated: April 10, 2013

Summary

FDA records drug Class I recall D-015-2014, published November 27, 2013 and initiated April 10, 2013. Recalling firm: Affirm XL, Inc.; Status: Terminated; Reported quantity: 400 pills; Lot: Lot# 1190001, exp 12/30/2013. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without An Approved NDA/ANDA: FDA analysis found the product to contain sulfoaildenafil, an analogue of sildenafil which is an ingredient in an FDA-approved drug for the treatment of male erectile dysfunction, making this an unapproved new drug.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Affirm XL, Inc.
Distributor
Nationwide in the US and Canada
Lot
Lot# 1190001, exp 12/30/2013
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Affirm XL Nutritional Supplement, 1 and 10 count blister packs and single pill packs, Manufactured by Dongseo Biopharm Corp., Yongin City, Kyonggi do, Korea, distributed by: Affirm XL, LLC, Ladera Ranch, CA recalled?

Yes. FDA published recall D-015-2014 on November 27, 2013. Reported hazard: Marketed Without An Approved NDA/ANDA: FDA analysis found the product to contain sulfoaildenafil, an analogue of sildenafil which is an ingredient in an FDA-approved drug for the treatment of male erectile dysfunction, making this an unapproved new drug.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release